A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages

Noriyuki Hayashi1, Hiromi Kataoka1, Shigenobu Yano2,3, Mamoru Tanaka1, Kazuhiro Moriwaki4, Haruo Akashi4, Shugo Suzuki5, Yoshinori Mori1, Eiji Kubota1, Satoshi Tanida1, Satoru Takahashi5, and Takashi Joh1

Abstract

Tumor-associated macrophages (TAM) in cancer stroma play important roles for cancer cell growth, invasion, angiogenesis, and metastases. We synthesized a novel photosensitizer, mannose-conjugated chlorin (M-chlorin), designed to bind mannose receptors highly expressed on TAMs. We evaluated the newly available photodynamic therapy (PDT) with M-chlorin against gastric and colon cancer. We evaluated PDT with M-chlorin for in vitro cytotoxicity and apoptosis induction in cancer cells compared with chlorin alone and glucose-conjugated chlorin (G-chlorin). The subcellular localization of M-chlorin was observed by confocal microscopy, and the M-chlorin PDT effects against TAMs including THP-1–induced M2-polarized macrophages were evaluated. Anticancer effects were also investigated in an allograft model where cytotoxic effects against TAMs in the cancer cell stroma were analyzed by immunohistochemistry. M-chlorin PDT strongly induced cell death in cancer cells to almost the same extent as G-chlorin PDT by inducing apoptosis. M-chlorin was incorporated into cancer cells where it localized mainly in lysosomes and endoplasmic reticula. M-chlorin PDT revealed strong cytotoxicity for M2 macrophages induced from THP-1 cell lines, and it induced stronger cytotoxicity than G-chlorin PDT in the allograft model through killing both cancer cells and TAMs in the cancer stroma. The M-chlorin PDT produced strong cytotoxicity against cancer tissue by inducing apoptosis of both cancer cells and TAMs in the cancer stroma. This novel PDT thus stands as a new candidate for very effective, next-generation PDT.

Introduction

Tumor stroma consists of activated fibroblasts, myofibroblasts, smooth muscle cells, endothelial cells, and inflammatory cells, including macrophages (1–5). Macrophages are often the most abundant immune cells in the tumor microenvironment and are key regulators of the inflammatory process during cancer. Macrophages migrating to tumor stroma are called tumor-associated macrophages (TAM; refs. 6–9). TAMs play several M2-associated protumoral roles during the cancer process including in tumor cell growth, angiogenesis, matrix remodeling, and metastases. Indeed, the abundance of TAMs has been correlated with poor prognosis in various types of human cancers (10–14). TAMs are known to specifically express abundant levels of CD206, a mannose receptor (15–17), which is also called the “pattern-recognition receptor.” These receptors are crucial for the macrophage’s role in engulfing invading organisms and degrading them through endocytosis and phagocytosis (18, 19).

Recently, TAMs have been investigated as novel therapeutic targets of cancer therapy (20–24). However, the therapies being trialed kill not only TAMs in cancer stroma, but also other M2 macrophages throughout the body that are important for normal processes including parasite containment, promotion of tissue remodeling, and immune regulation. Thus, targeting M2 macrophages systemically carries the risk of inducing an immunocompromised state (7, 25, 26).

Photodynamic therapy (PDT) is now an established treatment for cancer and some nonmalignant diseases (27). PDT uses the combination of nontoxic dyes or photosensitizers and harmless visible light to produce reactive oxygen species (ROS) and destroy tumors (28, 29). The anticancer effects of PDT are consequences of a low-to-moderately selective degree of photosensitizer uptake by malignant cells, direct cytotoxicity of ROS produced by photosensitizer and irradiation, and severe tumor vascular damage that impairs blood supply to the treated area (30–32). Importantly, these biologic effects of PDT are limited to the particular areas of tissues exposed to light.

PDT using porfimer sodium, a first-generation photosensitizer used clinically in Japan, has disadvantages such as the requirement for shielding from light for 4 to 6 weeks and a high incidence of skin toxicity due to the photosensitivity of porfimer sodium.
(33, 34). PDT with talaporfin, a second-generation photosensitizer, involves a shorter period of light shielding (about 2 weeks) and lower incidence of skin toxicity than PDT with porfimer sodium, and the wavelength of laser light used for talaporfin (664 nm) is longer than that needed to excite porfimer sodium (630 nm); thus, the talaporfin PDT effects may penetrate deeper into the tissue (33, 35). To improve the efficacy of PDT, photosensitizers with better cancer cell specificity and selectivity are needed. In our previous study, we reported that PDT using the newly developed photosensitizer, glucose-conjugated chlorin (G-chlorin), exerted approximately 30 times more cytotoxicity than talaporfin PDT (36). Cancer cells incorporate more glucose than normal cells in a phenomenon known as the Warburg effect (37), and we utilized this phenomenon for PDT like it is used diagnostically in fluorodeoxyglucose positron emission tomography/computed tomography (38-40). Accordingly, using a glucose-conjugated photosensitizer increased the cancer cell selectivity and specificity of PDT (36, 41).

On the basis of our previous study and other reports, we then proposed targeting TAMs using PDT to block cancer development. In this study, we examined antitumor effects by using newly synthesized mannose-conjugated chlorin (M-chlorin) to target mannose receptors on TAMs. This PDT approach is the first therapy to target only TAMs in cancer stroma without any systemic damage to M2 macrophages.

Materials and Methods

Photosensitizers

M-chlorin (H₂TFPC-SMan, 5, 10, 15, 20-tetakis (4- (α-D-mannopyranosylthio)-2, 3, 5, 6-tetrafluorophenyl)-2, 3-(methano (N-methyl) iminomethano) chlorin), G-chlorin (H₂TFPC-SGlc, 5, 10, 15, 20-tetakis (4- (β-D-glucopyranosylthio)-2, 3, 5, 6-tetrafluorophenyl)-2, 3-(methano (N-methyl) iminomethano) chlorin), and chlorin (H₂TFPC, 5, 10, 15, 20-tetakis (2, 3, 4, 5, 6-pentatfluorophenyl)-2, 3-(methano (N-methyl) iminomethano) chlorin) were synthesized and provided by the laboratory of the Japanese Cancer Research Resources Bank (MKN28, MKN45, HT29, HCT116, CT26) and M1, M2-polarized THP-1 macrophages were cultured in RPMI1640 (Sigma-Aldrich) supplemented with 10% FBS, 100 μg/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B. The human colon cancer cell lines HT29 (No. HTB-38, ATCC) and HCT116 (No.CCL-274, ATCC) were cultured in McCoy 5A Medium (Sigma-Aldrich) supplemented with 10% FBS, 100 μg/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B. The murine colorectal cancer cell line CT26 (No.CRL-2638, ATCC) was cultured in DMEM (Sigma-Aldrich) supplemented with 10% FBS, 100 μg/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B. The human monocytic cell line THP-1 (ATCC TIB202; ATCC) was cultured in RPMI1640 supplemented with 10% FBS, 100 μg/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B and 0.05 mmol/L 2-mercaptoethanol. Cells were cultured under an atmosphere of 5% CO₂ at 37°C.

To generate M1-polarized THP-1 macrophages, THP-1 cells were treated with 320 mmol/L phorbol myristate acetate (PMA) for 6 hours and cultured with PMA plus 20 ng/mL INFγ and 100 ng/mL lipopolysaccharide for 18 hours. To generate M2-polarized THP-1 macrophages, THP-1 cells were treated with 320 mmol/L PMA for 6 hours and cultured with PMA plus 20 ng/mL IL4 and 20 ng/mL IL13 for 18 hours (43).

Cell viability assay was performed to all human cancer cell lines (MKN28, MKN45, HT29, HCT116, and THP-1) by JCRB cell bank on February 25, 2014.

In vitro PDT

The gastric and colon cancer cells (MKN28, MKN45, HT29, HCT116, CT26) and M1, M2-polarized THP-1 macrophages were incubated with photosensitizer in culture medium for 24 hours. Cancer cells and macrophages were washed once in PBS, covered with PBS, and irradiated at 13.9 and 5.6 J/cm² (intensity: 30.8 mW/cm²) of LED light (Opto Code Corporation), which emits 660 nm wavelength.

Cell viability assay

Cell viability was determined using a WST-8 cell proliferation assay (Dojindo). Gastric and colon cancer cells and macrophages were seeded into 96-well culture plates at 5 × 10⁵ cells/100 μL well and incubated overnight. Cells were then incubated with photosensitizers at 37°C for 24 hours, irradiated, and incubated with culture medium for a further 24 hours. To determine survival, cells were incubated with cell counting kit-8 for 4 hours and...
absorption at 450 nm was measured with a microplate reader (SPECTRA MAX340, Molecular Devices). Cell viability was expressed as a percentage of treated cells versus untreated control cells. The half maximal (50%) inhibitory concentration (IC_{50}) was calculated.

Caspase-3/7 assay

Apoptosis in the CT26 cells was assessed using the Caspase-Glo3/7 Assay Kit (Promega) according to the manufacturer’s instructions. CT26 cells were seeded into 96-well culture plates and incubated overnight. Cells were then incubated with 0.2 μmol/L photosensitizers at 37°C for 24 hours and irradiated. Analyses were performed at 0, 1, 4, 8, and 12 hours after PDT by adding 50 μL of caspase-3/7 reagent to each well, mixing, and incubating for 1 hour at room temperature. Luminescence was measured using a Lu mat LB 9507 instrument (EG&G BERT-HOLD). Caspase-3/7 activity was expressed as percentage of the untreated control.

Intracellular localization of photosensitizers

CT26 cells were seeded into 24-well culture plates and incubated overnight. Cells were incubated with 0.2 μmol/L M-chlorin for 24 hours and stained with organelle-specific fluorescent probes, as follows: lysosomes with 0.1 μmol/L LysoTracker Green (Invitrogen) at 37°C for 30 minutes; mitochondria with 0.1 μmol/L MitoTracker Green FM (Invitrogen) at 37°C for 10 minutes; Golgi with 5 μmol/L NBD C6-ceramide at 4°C for 30 minutes; and endoplasmic reticulum with 0.1 μmol/L ER-Tracker Green (Invitrogen) at 37°C for 30 minutes. Following incubation, cells were rinsed with PBS to remove free dyes, and the stained cells were observed live by confocal laser microscopy (Nikon A1 confocal system Nikon Instech Co., Ltd.) and data were analyzed using NIS element imaging software (Nikon). Band-pass emission filters of 505 to 530 nm and 650 nm were used.

Real-time reverse transcription PCR

CD68, CD206, TNFα, and GAPDH mRNA expression in THP-1 and M1, M2-polarized THP-1 macrophages was measured by real-time reverse transcription PCR (RT-PCR). GAPDH was chosen as an endogenous control to normalize the expression data. mRNA was reverse transcribed into complementary DNA (cDNA) using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer’s instructions. TaqMan gene expression assays for CD68 (Hs02836816_g1), CD206 (Hs00267207_m1), TNFα (Hs01113624_g1), and GAPDH (Hs99999905_m1) were purchased from Applied Biosystems, and quantitative RT-PCR analyses were performed in triplicate using an ABI 7500 Fast Real-Time PCR system (Applied Biosystems) according to the supplier’s recommendations. All data are presented as fold changes of internal control.

Animals and tumor models

Female mice (BALB/c CrSlc) ages 4 weeks and weighing 20 to 25 g were obtained from Japan SLC. Animals were allowed to acclimatize for 2 weeks in the animal facility before any interventions were initiated. Allograft tumor models were established by implanting 1 × 10^6 colon cancer cells (CT26) subcutaneously under the right flank of BALB/c mice. The procedures in these experiments were approved by the Nagoya City University Center for Experimental Animal Science, and mice were raised according to the Nagoya City University for Animal Experiments.

In vivo PDT

When transplanted tumors grew to approximately 100 mm^3, mice were given an intraperitoneal injection of photosensitizer (chlorin, G-chlorin, M-chlorin) at a dose of 6.25 μmol/kg. At 24 hours after injection, tumors were irradiated with 660 nm LED at a dose of 13.9 J/cm^2. Irradiation was repeated twice on day 1 and day 8. Tumor growth was monitored by measuring tumor volume with vernier calipers, and calculated using the following formula: (length × width × height). Relative tumor growth was assessed by comparing tumor volume with that measured on day 1. Treated groups and control groups consisted of 5 mice and 4 mice, respectively. All in vivo assays were performed three times.

Immunohistochemistry of transplanted tumor

After treatment and in vivo measurements, the mice were deeply anesthetized and sacrificed at 3 days after the first irradiation (day 4). The tumors were immediately excised and were fixed in formalin for immunohistochemical examination. Anti-F4/80 (ab6640 Abcam) was used as a specific marker for macrophages, and anti-CD206 antibody (MCA2235T A Bio-Rad) was used as a specific marker for TAMs.

Consecutive tissue sections (4 μm thick) were deparaffinized in xylene and hydrated through a graded series of ethanol. After inhibition of endogenous peroxidase activity by immersion in 0.3% H_2O_2 methanol solution, sections were incubated with the primary antibody, washed thoroughly in PBS, and then incubated with biotinylated secondary antibody followed by the avidin-biotinylated horseradish peroxidase complex. Finally, immune complexes were visualized by incubation with 0.01% H_2O_2 and 0.05% 3,3'-diaminobenzidine tetrachloride (DAB). Nuclear counterstaining was accomplished with Mayer’s hematoxylin. Mouse macrophages and TAMs in a 250 × 250 μm area were counted in random triplicates of area from each mouse, and averaged.

Spectrometer analysis

The accumulation of photosensitizers in the allograft tumors was examined using a semiconductor laser with a VLD-M1 spectrometer (M&M Co., Ltd.) that emitted a laser light with a peak wavelength of 405 ± 1 nm and a light output of 140 mW. The spectrometer and its accessory software (BW-Spec V3.24; B&W

Table 1. The IC_{50} for gastric and colon cancer cells by chlorin, G-chlorin, and M-chlorin PDT

<table>
<thead>
<tr>
<th>Photosensitizer</th>
<th>Gastric cancer</th>
<th>Colon cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MKN28</td>
<td>MKN45</td>
</tr>
<tr>
<td>Chlorin</td>
<td>2.94</td>
<td>3.77</td>
</tr>
<tr>
<td>G-chlorin</td>
<td>0.20</td>
<td>0.16</td>
</tr>
<tr>
<td>M-chlorin</td>
<td>0.15</td>
<td>0.27</td>
</tr>
</tbody>
</table>

NOTE: Gastric and colon cancer cells (MKN28, MKN45, HT29, HCT116, and CT26) were incubated with various concentrations of photosensitizer in culture medium for 24 hours, irradiated with 13.9 J/cm^2 of 660 nm LED light, and incubated for 24 hours. Cell viability was determined by a WST-8 assay and expressed by 50% inhibitory concentration (IC_{50}). Data are means of five independent experiments.
We next investigated the level of apoptosis induced by M-chlorin–mediated PDT. Cells were incubated with 0.2 μmol/L photosensitizers (chlorin, G-chlorin, M-chlorin) for 24 hours, followed by irradiation with 660 nm (13.9 J/cm²), and measurement of caspase-3/7 activity at 0, 1, 4, 8, and 12 hours after PDT. As shown in Fig. 2, PDT with G-chlorin and M-chlorin induced apoptosis from 1 hour after irradiation, with the maximal effects found at 8 hours with G-chlorin and at 4 hours with M-chlorin. PDT with chlorin alone did not activate caspase-3/7 significantly.

M-chlorin was incorporated into cancer cells and mainly localized in lysosomes and endoplasmic reticula.

Next, we investigated the subcellular localization of M-chlorin by confocal microscopy using fluorescence probes for intracellular organelles. Cells were loaded with M-chlorin and incubated with MitoTracker Green, LysoTracker Green, NBD C6 ceramide Green, or ERTracker Green to label mitochondria, lysosomes, Golgi, or endoplasmic reticulum, respectively. M-chlorin tended to colocalize with LysoTracker and ERTracker, indicating accumulation in lysosomes and endoplasmic reticulum (Fig. 3). On the other hand, G-chlorin seemed to colocalize with MitoTracker, indicating accumulation in mitochondria (Supplementary Fig. S2).

**Results**

**PDT with M-chlorin strongly induced cell death in M2 macrophages**

M1, M2-polarized THP-1 macrophages (CD68 positive) were generated as described previously (43), and compared with THP-1 cells. As shown in Fig. 4A, M1- and M2-polarized THP-1 macrophages expressed significantly higher CD68 than undifferentiated THP-1 macrophages (P < 0.01). The M2-polarized THP-1 macrophages also expressed significantly higher mannose receptor.

The statistical significance of differences was determined using the Student’s t test or the Tukey–Kramer method. Differences were considered statistically significant at P < 0.05. Data are expressed as means ± SE.

**Statistical analysis**

TEK, Inc.) were used to analyze the spectrum waveform and revealed an amplitude peak (relative fluorescent intensity) at 505 nm for autofluorescence, and at 655 nm for photosensitizers. The relative intensities of the photosensitizers were measured by the spectrometer. To reduce measurement error, the relative fluorescence intensity ratios of photosensitizers in the target tissue, which were calculated by dividing the relative fluorescence intensity by that of autofluorescence, were compared.

**PDT Targeting Tumor-Associated Macrophages**

**Figure 2.**

Caspase-3/7 activity in CT26 cells after PDT. CT26 cells were incubated with 0.2 μmol/L photosensitizers (chlorin, G-chlorin, M-chlorin) or negative control, and irradiated with 13.9 J/cm² of 660 nm LED light. Analyses were performed at 0, 1, 4, 8, and 12 hours after PDT. Caspase-3/7 activity was determined by the Caspase-Glo3/7 Assay and expressed as percentages of untreated control. Data are means ± SE of six independent experiments. *P < 0.05, G-chlorin and M-chlorin at 0 hour versus G-chlorin and M-chlorin at 4 hours; **P < 0.01, G-chlorin at 0 hour versus G-chlorin at 8 hours.

**Figure 3.**

Subcellular localization of M-chlorin. CT26 cells were loaded with M-chlorin for 24 hours and labeled with MitoTracker Green, LysoTracker Green, NBD C6 ceramide Green, or ERTracker Green. The images were obtained by confocal microscopy (Original magnification, ×1000; scale bar, 5 μm).
Than the THP-1 cells and M1-polarized THP-1 macrophages \((P < 0.01; \text{Fig. 4B})\), while TNF\(\alpha\) mRNA expression was increased significantly in M1-polarized THP-1 macrophages compared with THP-1 cells and M2-polarized THP-1 macrophages \((P < 0.0005; \text{Fig. 4C})\).

Then, we evaluated the M2 macrophage death induced by PDT with M-chlorin. M1, M2-polarized THP-1 macrophages were then loaded with 1 \(\mu\)mol/L photosensitizer (chlorin, G-chlorin, M-chlorin) for 24 hours and irradiated at 5.6 J/cm\(^2\). PDT with chlorin, G-chlorin, and M-chlorin was equally effective against M1-polarized macrophages (Fig. 4D), but PDT with M-chlorin induced cell death more effectively in M2 macrophages than PDT with chlorin or G-chlorin (Fig. 4E). These findings revealed that PDT with M-chlorin selectivity induced cell death against M2 macrophages compared with PDT with chlorin or G-chlorin.

**M-chlorin PDT strongly suppressed tumor growth in vivo**

To examine the effects of M-chlorin PDT on tumors in vivo, PDT was performed on allograft models established by subcutaneously implanting mouse colon cancer cells (CT26) into mice models. When tumors grew, mice were given an intraperitoneal injection of photosensitizers, and 24 hours later were irradiated. PDT was performed two times on day 1 and day 8. M-chlorin PDT mediated significantly suppressed tumor growth compared with control treatment, chlorin PDT, and G-chlorin PDT (Fig. 5).

**M-chlorin PDT attacks TAMs**

Finally, we analyzed tumors for the selective elimination of TAMs from the tumor stroma after M-chlorin PDT using an anti-F4/80 antibody to stain macrophages and an anti-CD206 (mannose receptor) antibody to stain TAMs (Fig. 6A). Mouse macrophages and TAMs in a 250 \(\times\) 250 \(\mu\)m area were counted in triplicate and averaged. Both F4/80-positive macrophages and CD206-positive TAMs in the tumor stroma were significantly decreased by M-chlorin and G-chlorin PDT compared with respective numbers in the control and chlorin PDT groups \((P < 0.01)\) (Fig. 6B). As shown in Fig. 6C, the ratio of TAMs/macrophages in tumor stroma treated by M-chlorin was significantly decreased compared with those in the control, chlorin, and G-chlorin groups \((P < 0.01)\). These results
were monitored for 13 days in total. Data are means ± SE (n = 4 for control, n = 5 for chlorin, G-chlorin, and M-chlorin). *P < 0.05, **P < 0.01.

indicated that PDT with M-chlorin effectively induced cell death against TAMs infiltrated into cancer stroma and that this could explain, at least in part, how M-chlorin PDT induces strong antitumor effects in an allograft model.

Discussion

Macrophages activated by bacterial products and Th1 cytokines are regarded as M1 macrophages, which are classically activated macrophages with high anti-bacterial activity and cytotoxicity against cancer cells. On the other hand, macrophages activated by Th2 cytokines such as IL4 and IL13 or immune suppressors such as IL10 are classified as M2 macrophages, which have low cytotoxicity, but strong tissue-remodeling activity (1, 7, 8, 26). TAMs are predominantly M2 macrophages induced to accumulate in tumor stroma by chemokines from the cancer cells such as monocyte chemotactic protein-1 (MCP-1), macrophage colony stimulating factor (M-CSF or CSF-1), and VEGF (2, 6).

TAMs express mannose receptors and thus traffic endosomes via early and late endosomes.

We therefore analyzed the expression of four mannose receptor family members, mannose receptor (MR), M-type phospholipase A2 receptor (PLA2R), DEC-205/gp200-MR6, and Endo 180/ uPARAP by quantitative real-time RT-PCR in gastric and colon cancer cells, and found various expression levels (Supplementary Fig. S3). We therefore speculated that the cancer cells tested also use mannose receptor family members for endocytosis just like macrophages.

The mannose receptor family is a subgroup of the C-type lectin superfamily and comprises four members: the mannose receptor (MR), the M-type phospholipase A2 receptor (PLA2R), DEC-205/gp200-MR6, and Endo 180/uPARAP (18, 19, 45). These receptors consist of a type I transmembrane receptor with an N-terminal cysteine-rich domain, a single fibronectin type II (FN II) domain, and 8–10 C-type lectin-like domains, and all play crucial roles in endocytosis and phagocytosis by recycling between the plasma membrane and the endosomal apparatus (18). The MR also plays crucial roles in the innate and adaptive immune systems, while the PLA2R can internalize soluble PLA2 enzymes, DEC-205 functions in the internalization of antigen for presentation to T lymphocytes, and Endo180 is involved in remodeling of the ECM (18). Our confocal microscopy studies showed that M-chlorin was mainly localized in lysosomes and ER after PDT in the CT26 cancer cells, consistent with the mannose receptors’ important roles in the endocytosis to lysosome pathway. We speculate that M-chlorin may be trapped by mannose receptors and thus trafficked by endocytosis to lysosomes via early and late endosomes.

PDT with M-chlorin induced apoptosis in cancer cells (CT26) with the peak at 4 hours after irradiation. Western blotting of nuclear protein showed that PDT with M-chlorin increased nuclear translocation of Nrf2 gradually from 0.5 hours onward after PDT (Supplementary Fig. S4), indicating ROS generation and subsequent disruption of the Nrf2/Keap1 association, leading to the nuclear translocation of Nrf2.

Although PDT with M-chlorin and G-chlorin were almost equally effective at targeting tumor cells in vitro, M-chlorin-mediated PDT in vivo significantly suppressed tumor growth than G-chlorin–mediated PDT. In addition, M-chlorin and G-chlorin specifically accumulated on tumor region than chlorin in vivo (Supplementary Fig. S5). We therefore speculated that the difference in efficacy between M-chlorin PDT and G-chlorin PDT could lie in the difference of effects against TAMs in tumor stroma. Further investigation of TAMs in the tumor stroma by CD206 fluorescence immunostaining of frozen sections revealed that more M-chlorin tended to accumulate on CD206-expressing TAMs than G-chlorin does (Supplementary Fig. S6). These findings explain the reason why M-chlorin specifically kill the CD206–expressing TAMs (Fig. 6B and C).

Figure 6 represents the striking change in the observed pattern of F4/80-positive macrophage distribution following PDT with G- and M-chlorin. Both these agents accumulated on F4/80-positive macrophages in the tumor, whereas M-chlorin tended to accumulate on CD206-positive TAMs more specifically than G-chlorin. This could explain why M-chlorin has significantly stronger effects against CD206-positive TAMs compared with G-chlorin (Fig. 6C). Furthermore, M-chlorin PDT was specifically effective against M2-polarized THP-1 macrophages that highly express mannose receptors. We also revealed that excess mannose reduced the binding of M-chlorin to the macrophages and tumor cells in dose-dependent manner (Supplementary Fig. S7). On the
basis of these findings, we propose that the cytotoxic effects of M-chlorin PDT on both cancer cells and TAMs expressing high levels of mannose receptor might translate to very strong anticancer effects in an allograft model.

In recent years, many reports showed that TAMs are strongly associated with advanced tumor stage and poor progress in several types of cancer (12, 14, 46). Consequently, therapeutic targeting of TAMs has been proposed for cancer therapy to delay tumor growth (20–22, 25). Mannose receptor is a pathogen recognition receptor and the major receptor responsible for endocytosis in dendritic cells (47). Thus, while M-chlorin may accumulate on the systemic populations of M2 macrophages, the cytotoxic effects of M-chlorin PDT might only affect the tumor microenvironment under irradiation. Peptide therapy or DNA vaccine therapy against M2 macrophages expressing high levels of mannose receptors were reported to be beneficial against cancer (16, 20, 22), but these therapies attack not only TAMs in cancer stroma, but also M2 macrophages throughout the body, risking the induction of immunosuppression. Such a risk would not be an issue with our M-chlorin PDT therapy, which targets only TAMs in tumor stroma and thus should not affect immune responses elsewhere.

Figure 6. Immunohistochemistry of allograft tumors. Mice were irradiated with 13.9 J/cm² of LED light at 660 nm 24 hours after injection and then were deeply anesthetized and killed at 3 days after illumination. The tumors were immediately excised and fixed in formalin for immunohistochemical examination. A, the anti-F4/80 antibody was used as a specific marker for macrophages and the anti-CD206 antibody was used as a specific marker for TAMs. Sections were stained with HE (left), anti-F4/80 (middle) antibodies, and anti-CD206 (right) antibodies. Magnification ×100. B, macrophages (F4/80-positive cells) and TAMs (CD206-positive cells) in 250 × 250 μm of tumor images were counted in triplicate. C, the ratio of TAMs to macrophages in tumor filtrates (TAMs/macrophages) from the control, chlorin, G-chlorin, and M-chlorin PDT groups. *, P < 0.01, G-chlorin, and M-chlorin versus control; **, P < 0.01, M-chlorin versus control, chlorin, and G-chlorin.
In conclusion, we evaluated the anticancer effects of targeting TAMs via PDT with M-chlorin. The specific suppression of TAMs in cancer stroma significantly suppressed tumor growth in allograft models. Such therapeutic targeting of TAMs as well as cancer cells may represent a new strategy for anticancer therapy.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: H. Kataoka, S. Yano
Development of methodology: H. Kataoka, M. Tanaka
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): H. Kataoka, S. Suzuki, Y. Mori, S. Takahashi
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): H. Kataoka, M. Tanaka, S. Suzuki, E. Kubota, S. Tanida
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M. Tanaka, E. Kubota, S. Takahashi
Writing, review, and/or revision of the manuscript: N. Hayashi, H. Kataoka
Study supervision: H. Kataoka, S. Tanida, T. Joh

Other (preparation of compounds): K. Moriwaki, H. Akashi

Acknowledgments

The authors thank Yukimi Ito and Chiaki Koike at Nagoya City University Graduate School of Medical Sciences for technical assistance. The authors also thank Prof. Hideya Yuasa of the Tokyo Institute of Technology for helpful discussions.

Grant Support

This work was financially supported by JSPS KAKENHI grant number 23590923, JSPS KAKENHI grant number 24790717, JSPS KAKENHI grant number 25288028, JSPS KAKENHI grant number 213935031, JSPS KAKENHI grant number 5280028, the Japan-Germany Exchange Program supported by the JSPS and the Deutsche Forschungsgemeinschaft, the Hori Sciences and Arts Foundation (2013), Japan Science and Technology Agency A-step (2011), Japan Science and Technology Agency Molecular Imaging (2011, 2012, 2013), and The Japanese Foundation for Research and Promotion of Endoscopy (2011).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


References

Molecular Cancer Therapeutics

A Novel Photodynamic Therapy Targeting Cancer Cells and Tumor-Associated Macrophages

Noriyuki Hayashi, Hiromi Kataoka, Shigenobu Yano, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-14-0348</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://mct.aacrjournals.org/content/suppl/2014/12/16/1535-7163.MCT-14-0348.DC1">http://mct.aacrjournals.org/content/suppl/2014/12/16/1535-7163.MCT-14-0348.DC1</a></td>
</tr>
<tr>
<td>Cited articles</td>
<td>This article cites 46 articles, 19 of which you can access for free at: <a href="http://mct.aacrjournals.org/content/14/2/452.full.html#ref-list-1">http://mct.aacrjournals.org/content/14/2/452.full.html#ref-list-1</a></td>
</tr>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 2 HighWire-hosted articles. Access the articles at: /content/14/2/452.full.html#related-urls</td>
</tr>
</tbody>
</table>

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.